[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fpVx3ubZ6UfljeRB_wKVwAYOCoEuGXhih9TIWqtbYBsI":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":43,"rows":50},"Vestre Viken Hospital Trust",[4],63,false,24,1,21495,4,53,[14,16,19,21,23,26,28,30],{"name":15,"count":11},"Cardiovascular Diseases",{"name":17,"count":18},"Atrial Fibrillation",3,{"name":20,"count":18},"Nurse's Role",{"name":22,"count":18},"Osteoarthritis",{"name":24,"count":25},"Quality of Life",2,{"name":27,"count":25},"Frailty",{"name":29,"count":25},"Pneumonia",{"name":31,"count":25},"Smoking Cessation",[33,38],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT05731453","Clinical Pilot Study for Personalized Risk-based Breast Cancer Screening","2024-05-01","Polygenetic risk score",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT05344209","Efficacy and Safety of Anti-PD-1\u002FPD-L1 Treatment +\u002F- UV1 Vaccination in Patients With Non-small Cell Lung Cancer","2025-07-01","UV1",[44,45,46,47,48,49],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[51,79,97,115,138,167,185,210,234,262,290,308,338,362],{"intervention":42,"totalTrials":9,"cells":52},{"EARLY_PHASE1":53,"PHASE1":56,"PHASE2":58,"PHASE3":73,"PHASE4":75,"NA":77},{"trials":54,"activeCount":55},[],0,{"trials":57,"activeCount":55},[],{"trials":59,"activeCount":9,"soonestReadout":41},[60],{"nctId":39,"briefTitle":40,"status":61,"phases":62,"primaryCompletion":41,"completion":63,"start":64,"enrollment":65,"conditions":66,"interventions":70},"RECRUITING",[46],"2027-07-01","2022-08-12",138,[67,68,69],"Oncology","NSCLC Stage IV","NSCLC, Stage III",[42,71,72],"Sagramostim","Anti-PD-1\u002FPD-L1 treatment",{"trials":74,"activeCount":55},[],{"trials":76,"activeCount":55},[],{"trials":78,"activeCount":55},[],{"intervention":71,"totalTrials":9,"cells":80},{"EARLY_PHASE1":81,"PHASE1":83,"PHASE2":85,"PHASE3":91,"PHASE4":93,"NA":95},{"trials":82,"activeCount":55},[],{"trials":84,"activeCount":55},[],{"trials":86,"activeCount":9,"soonestReadout":41},[87],{"nctId":39,"briefTitle":40,"status":61,"phases":88,"primaryCompletion":41,"completion":63,"start":64,"enrollment":65,"conditions":89,"interventions":90},[46],[67,68,69],[42,71,72],{"trials":92,"activeCount":55},[],{"trials":94,"activeCount":55},[],{"trials":96,"activeCount":55},[],{"intervention":72,"totalTrials":9,"cells":98},{"EARLY_PHASE1":99,"PHASE1":101,"PHASE2":103,"PHASE3":109,"PHASE4":111,"NA":113},{"trials":100,"activeCount":55},[],{"trials":102,"activeCount":55},[],{"trials":104,"activeCount":9,"soonestReadout":41},[105],{"nctId":39,"briefTitle":40,"status":61,"phases":106,"primaryCompletion":41,"completion":63,"start":64,"enrollment":65,"conditions":107,"interventions":108},[46],[67,68,69],[42,71,72],{"trials":110,"activeCount":55},[],{"trials":112,"activeCount":55},[],{"trials":114,"activeCount":55},[],{"intervention":37,"totalTrials":9,"cells":116},{"EARLY_PHASE1":117,"PHASE1":119,"PHASE2":121,"PHASE3":123,"PHASE4":125,"NA":127},{"trials":118,"activeCount":55},[],{"trials":120,"activeCount":55},[],{"trials":122,"activeCount":55},[],{"trials":124,"activeCount":55},[],{"trials":126,"activeCount":55},[],{"trials":128,"activeCount":9,"soonestReadout":36},[129],{"nctId":34,"briefTitle":35,"status":130,"phases":131,"primaryCompletion":36,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":137},"ACTIVE_NOT_RECRUITING",[49],"2035-11-11","2023-02-01",80,[136],"Breast Cancer",[37],{"intervention":139,"totalTrials":9,"cells":140},"Ropivacaine",{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":165},{"trials":142,"activeCount":55},[],{"trials":144,"activeCount":55},[],{"trials":146,"activeCount":55},[],{"trials":148,"activeCount":55},[],{"trials":150,"activeCount":55},[151],{"nctId":152,"briefTitle":153,"status":154,"phases":155,"primaryCompletion":156,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":163},"NCT02949778","Quadratus Lumborum Block for Abdominoplasty","COMPLETED",[48],"2017-06-15","2017-12-13","2016-11-07",50,[161,162],"Pain, Postoperative","Abdominoplasty",[139,164],"Sodium Chloride",{"trials":166,"activeCount":55},[],{"intervention":164,"totalTrials":9,"cells":168},{"EARLY_PHASE1":169,"PHASE1":171,"PHASE2":173,"PHASE3":175,"PHASE4":177,"NA":183},{"trials":170,"activeCount":55},[],{"trials":172,"activeCount":55},[],{"trials":174,"activeCount":55},[],{"trials":176,"activeCount":55},[],{"trials":178,"activeCount":55},[179],{"nctId":152,"briefTitle":153,"status":154,"phases":180,"primaryCompletion":156,"completion":157,"start":158,"enrollment":159,"conditions":181,"interventions":182},[48],[161,162],[139,164],{"trials":184,"activeCount":55},[],{"intervention":186,"totalTrials":9,"cells":187},"Atorvastatin mylan 40 Mg Oral",{"EARLY_PHASE1":188,"PHASE1":190,"PHASE2":192,"PHASE3":194,"PHASE4":196,"NA":208},{"trials":189,"activeCount":55},[],{"trials":191,"activeCount":55},[],{"trials":193,"activeCount":55},[],{"trials":195,"activeCount":55},[],{"trials":197,"activeCount":55},[198],{"nctId":199,"briefTitle":200,"status":154,"phases":201,"primaryCompletion":202,"completion":202,"start":203,"enrollment":204,"conditions":205,"interventions":207},"NCT04453735","MUscle Side-Effects of Atorvastatin in Coronary Patients (MUSE) -Follow-up Study",[48],"2020-12-18","2020-08-19",27,[206],"Statin Adverse Reaction",[186],{"trials":209,"activeCount":55},[],{"intervention":211,"totalTrials":9,"cells":212},"Atorvastatin 40mg",{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":219,"PHASE4":221,"NA":232},{"trials":214,"activeCount":55},[],{"trials":216,"activeCount":55},[],{"trials":218,"activeCount":55},[],{"trials":220,"activeCount":55},[],{"trials":222,"activeCount":55},[223],{"nctId":224,"briefTitle":225,"status":154,"phases":226,"primaryCompletion":227,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":231},"NCT03874156","MUscle Side-Effects of Atorvastatin in Coronary Patients",[48],"2019-12-12","2019-03-05",77,[206],[211],{"trials":233,"activeCount":55},[],{"intervention":235,"totalTrials":9,"cells":236},"dalteparin 5000 IU s.c.",{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":243,"PHASE4":245,"NA":260},{"trials":238,"activeCount":55},[],{"trials":240,"activeCount":55},[],{"trials":242,"activeCount":55},[],{"trials":244,"activeCount":55},[],{"trials":246,"activeCount":55},[247],{"nctId":248,"briefTitle":249,"status":154,"phases":250,"primaryCompletion":251,"completion":252,"start":253,"enrollment":134,"conditions":254,"interventions":259},"NCT01714297","Preoperative Versus Postoperative Start With Thromboprophylaxis in THA (Total Hip Arthroplasty)",[48],"2008-06","2009-04","2008-01",[255,256,257,258],"Arthritis of the Hip","Transfusion Related Complications","Infection","Wound Discharge",[235],{"trials":261,"activeCount":55},[],{"intervention":263,"totalTrials":9,"cells":264},"Zoledronic Acid",{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":286,"NA":288},{"trials":266,"activeCount":55},[],{"trials":268,"activeCount":55},[],{"trials":270,"activeCount":55},[],{"trials":272,"activeCount":55},[273],{"nctId":274,"briefTitle":275,"status":276,"phases":277,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":284},"NCT04303026","The Effect of Zoledronic Acid on Patients With Osteoarthritis of the Hip","UNKNOWN",[47],"2023-06-30","2024-06-30","2020-03-02",70,[283],"Osteoarthritis, Hip",[263,285],"Saline 0.9%",{"trials":287,"activeCount":55},[],{"trials":289,"activeCount":55},[],{"intervention":285,"totalTrials":9,"cells":291},{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":296,"PHASE3":298,"PHASE4":304,"NA":306},{"trials":293,"activeCount":55},[],{"trials":295,"activeCount":55},[],{"trials":297,"activeCount":55},[],{"trials":299,"activeCount":55},[300],{"nctId":274,"briefTitle":275,"status":276,"phases":301,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":302,"interventions":303},[47],[283],[263,285],{"trials":305,"activeCount":55},[],{"trials":307,"activeCount":55},[],{"intervention":309,"totalTrials":9,"cells":310},"sotorasib",{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":332,"PHASE4":334,"NA":336},{"trials":312,"activeCount":55},[],{"trials":314,"activeCount":55},[],{"trials":316,"activeCount":55},[317],{"nctId":318,"briefTitle":319,"status":276,"phases":320,"primaryCompletion":321,"completion":322,"start":323,"enrollment":324,"conditions":325,"interventions":331},"NCT05311709","Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities",[46],"2024-10-01","2025-03-01","2022-05-30",100,[326,69,68,327,328,329,330],"Lung Cancer","Lung Cancer Stage IV","Mutation","Cancer","Cancer, Lung",[309],{"trials":333,"activeCount":55},[],{"trials":335,"activeCount":55},[],{"trials":337,"activeCount":55},[],{"intervention":339,"totalTrials":9,"cells":340},"osimertinib",{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":356,"PHASE4":358,"NA":360},{"trials":342,"activeCount":55},[],{"trials":344,"activeCount":55},[],{"trials":346,"activeCount":55},[347],{"nctId":348,"briefTitle":349,"status":276,"phases":350,"primaryCompletion":351,"completion":352,"start":353,"enrollment":324,"conditions":354,"interventions":355},"NCT03804580","First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer",[46],"2025-06-01","2025-12-31","2018-12-01",[326],[339],{"trials":357,"activeCount":55},[],{"trials":359,"activeCount":55},[],{"trials":361,"activeCount":55},[],{"intervention":363,"totalTrials":9,"cells":364},"Fampyra",{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":371,"PHASE4":373,"NA":375},{"trials":366,"activeCount":55},[],{"trials":368,"activeCount":55},[],{"trials":370,"activeCount":55},[],{"trials":372,"activeCount":55},[],{"trials":374,"activeCount":55},[],{"trials":376,"activeCount":55},[377],{"nctId":378,"briefTitle":379,"status":276,"phases":380,"primaryCompletion":381,"start":382,"enrollment":159,"conditions":383,"interventions":386},"NCT01720849","Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis",[],"2016-05","2012-12",[384,385],"Multiple Sclerosis","EDSS 4-7",[363]]